Noticeable Decreased Expression of Tenascin-X in Calcific Aortic Valves

References

• Katz, R., Wong, N.D., Kronmal, R., Takasu, J., Shavelle, D.M., Probstfield, J.L., Bertoni, A.G., Budoff, M.J., and O’Brien, K.D. (2006). Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis. Circulation 113:2113–2119.
   PubMed Web of Science ®Google Scholar
• Otto, C.M. (2009). Calcific aortic valve disease: Outflow obstruction is the end stage of a systemic disease process. Eur. Heart J. 30:1940–1942.
   PubMed Web of Science ®Google Scholar
• Mohler III, E.R., Gannon, F., Reynolds, C., Zimmerman, R., Keane, M.G., and Kaplan, F.S. (2001). Bone formation and inflammation in cardiac valves. Circulation 103:1522–1528.
   PubMed Web of Science ®Google Scholar
• Mohler III, E.R. (2004). Mechanisms of aortic valve calcification. Am. J. Cardiol. 94:1396–1402.
   PubMed Web of Science ®Google Scholar
• O’Brien, K.D., Kuusisto, J., Reichenbach, D.D., Ferguson, M., Giachelli, C., Alpers, C.E., and Otto, C.M. (1995). Osteopontin is expressed in human aortic valvular lesions. Circulation 92:2163–2168.
   PubMed Web of Science ®Google Scholar
• Freeman, R.V., and Otto, C.M. (2005). Spectrum of calcific aortic valve disease: Pathogenesis, disease progression, and treatment strategies. Circulation 111:3316–3326.
   PubMed Web of Science ®Google Scholar
• Beckmann, E., Grau, J.B., Sainger, R., Poggio, P., and Ferrari, G. (2010). Insights into the use of biomarkers in calcific aortic valve disease. J. Heart Valve Dis. 19:441–452.
   PubMed Web of Science ®Google Scholar
• Ross, P.L., Huang, Y.N., Marchese, J.N., Williamson, B., Parker, K., Hattan, S., Khainovski, N., Pillai, S., Dey, S., Daniels, S., Purkayastha, S., Juhasz, P., Martin, S., Bartlet-Jones, M., He, F., Jacobson, A., and Pappin, D.J. (2004). Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 3:1154–1169.
   PubMed Web of Science ®Google Scholar
• Matsumoto, K. (2012). Phosphorylation of extracellular matrix tenascin-X detected by differential mass tagging followed by nanoLC-MALDI-TOF/TOF-MS/MS using ProteinPilot software. Connect. Tissue Res. 53:106–116.
   PubMed Web of Science ®Google Scholar
• Matsumoto, K., Maniwa, T., Tanaka, T., Satoh, K., Okunishi, H., and Oda, T. (2012). Proteomic analysis of calcified abdominal and thoracic aortic aneurysms. Int. J. Mol. Med. 30:417–429.
   Google Scholar
• Tucker, R.P., Drabikowski, K., Hess, J.F., Ferralli, J., Chiquet-Ehrismann, R., and Adams, J.C. (2006). Phylogenetic analysis of the tenascin gene family: Evidence of origin early in the chordate lineage. BMC Evol. Biol. 6:60.
   PubMed Web of Science ®Google Scholar
• Matsumoto, K., Arai, M., Ishihara, N., Ando, A., Inoko, H., and Ikemura, T. (1992). Cluster of fibronectin type III repeats found in the human major histocompatibility complex class III region shows the highest homology with the repeats in an extracellular matrix protein, tenascin. Genomics 12:485–491.
   PubMedGoogle Scholar
• Bristow, J., Tee, M.K., Gitelman, S.E., Mellon, S.H., and Miller, W.L. (1993). Tenascin-X: A novel extracellular matrix protein encoded by the human XB gene overlapping P450c21B. J. Cell Biol. 122:265–278.
   PubMed Web of Science ®Google Scholar
• Lethias, C., Descollonges, Y., Boutillon, M.M., and Garrone, R. (1996). Flexilin: A new extracellular matrix glycoprotein localized on collagen fibrils. Matrix Biol. 15:11–19.
   PubMed Web of Science ®Google Scholar
• Matsumoto, K., Saga, Y., Ikemura, T., Sakakura, T., and Chiquet-Ehrismann, R. (1994). The distribution of tenascin-X is distinct and often reciprocal to that of tenascin-C. J. Cell Biol. 125:483–493.
   PubMed Web of Science ®Google Scholar
• Mao, J.R., Taylor, G., Dean, W.B., Wagner, D.R., Afzal, V., Lotz, J.C., Rubin, E.M., and Bristow, J. (2002). Tenascin-X deficiency mimics Ehlers-Danlos syndrome in mice through alteration of collagen deposition. Nat. Genet. 30:421–425.
   PubMed Web of Science ®Google Scholar
• Veit, G., Hansen, U., Keene, D.R., Bruckner, P., Chiquet-Ehrismann, R., Chiquet, M., and Koch, M. (2006). Collagen XII interacts with avian tenascin-X through its NC3 domain. J. Biol. Chem. 281:27461–27470.
   PubMed Web of Science ®Google Scholar
• Minamitani, T., Ikuta, T., Saito, Y., Takebe, G., Sato, M., Sawa, H., Nishimura, T., Nakamura, F., Takahashi, K., Ariga, H., and Matsumoto, K. (2004). Modulation of collagen fibrillogenesis by tenascin-X and type VI collagen. Exp. Cell Res. 298:305–315.
   PubMed Web of Science ®Google Scholar
• Egging, D., van den Berkmortel, F., Taylor, G., Bristow, J., and Schalkwijk, J. (2007). Interactions of human tenascin-X domains with dermal extracellular matrix molecules. Arch. Dermatol. Res. 298:389–396.
   PubMed Web of Science ®Google Scholar
• Margaron, Y., Bostan, L., Exposito, J.Y., Malbouyres, M., Trunfio-Sfarghiu, A.M., Berthier, Y., and Lethias, C. (2010). Tenascin-X increases the stiffness of collagen gels without affecting fibrillogenesis. Biophys. Chem. 14:87–91.
   Google Scholar
• Zweers, M.C., van Vlijmen-Willems, I.M., van Kuppevelt, T.H., Mecham, R.P., Steijlen, P.M., Bristow, J., and Schalkwijk, J. (2004). Deficiency of tenascin-X causes abnormalities in dermal elastic fiber morphology. J. Invest. Dermatol. 122:885–891.
   PubMed Web of Science ®Google Scholar
• Elefteriou, F., Exposito, J.Y., Garrone, R., and Lethias, C. (2001). Binding of tenascin-X to decorin. FEBS Lett. 495:44–47.
   PubMed Web of Science ®Google Scholar
• Schalkwijk, J., Zweers, M.C., Steijlen, P.M., Dean, W.B., Taylor, G., van Vlijmen, I.M., van Haren, B., Miller, W.L., and Bristow, J. (2001). A recessive form of the Ehlers-Danlos syndrome caused by tenascin-X deficiency. N. Engl. J. Med. 345:1167–1175.
   PubMed Web of Science ®Google Scholar
• Zweers, M.C., Peeters, A.C., Graafsma, S., Kranendonk, S., van der Vliet, J.A., den Heijer, M., and Schalkwijk, J. (2006). Abdominal aortic aneurysm is associated with high serum levels of tenascin-X and decreased aneurysmal tissue tenascin-X. Circulation 113:1702–1707.
   PubMed Web of Science ®Google Scholar
• Satoh, K., Tsukamoto, M., Shindoh, M., Totsuka, Y., Oda, T., and Matsumoto, K. (2010). Increased expression of tenascin-X in thoracic and abdominal aortic aneurysm tissues. Biol. Pharm. Bull. 33: 1898–1902.
   PubMed Web of Science ®Google Scholar
• Shilov, I.V., Seymour, S.L., Patel, A.A., Loboda, A., Tang, W.H., Keating, S.P., Hunter, C.L., Nuwaysir, L.M., and Schaeffer, D.A. (2007). The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. Mol. Cell. Proteomics 6:1638–1655.
   PubMed Web of Science ®Google Scholar
• Sturn, A., Quackenbush, J., and Trajanoski, Z. (2002). Genesis: Cluster analysis of microarray data. Bioinformatics 18:207–208.
   PubMed Web of Science ®Google Scholar
• Ikuta, T., Ariga, H., and Matsumoto, K. (2000). Extracellular matrix tenascin-X in combination with vascular endothelial growth factor B enhances endothelial cell proliferation. Genes Cells 5:913–927.
   PubMed Web of Science ®Google Scholar
• Walldius, G., and Jungner, I. (2006). The apoB/apoA-I ratio: A strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy-a review of the evidence. J. Intern. Med. 259:493–519.
   PubMed Web of Science ®Google Scholar
• Stan, S., Delvin, E., Lambert, M., Seidman, E., and Levy, E. (2003). Apo A-IV: An update on regulation and physiologic functions. Biochim. Biophys. Acta 1631:177–187.
   PubMed Web of Science ®Google Scholar
• Olofsson, S.O., and Borèn, J. (2005). Apolipoprotein B: A clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. J. Intern. Med. 258:395–410.
   PubMed Web of Science ®Google Scholar
• Kaschina, E., Scholz, H., Steckelings, U.M., Sommerfeld, M., Kemnitz, U.R., Artuc, M., Schmidt, S., and Unger, T. (2009). Transition from atherosclerosis to aortic aneurysm in humans coincides with an increased expression of RAS components. Atherosclerosis 205:396–403.
   PubMed Web of Science ®Google Scholar
• Kendrick, J., and Chonchol, M. (2011). The role of phosphorus in the development and progression of vascular calcification. Am. J. Kidney Dis. 58:826–834.
   PubMed Web of Science ®Google Scholar
• Tasheva, E.S., Koester, A., Paulsen, A.Q., Garrett, A.S., Boyle, D.L., Davidson, H.J., Song, M., Fox, N., and Conrad, G.W. (2002). Mimecan/osteoglycin-deficient mice have collagen fibril abnormalities. Mol. Vis. 8:407–415.
   PubMed Web of Science ®Google Scholar
• Reed, C.C., and Iozzo, R.V. (2002). The role of decorin in collagen fibrillogenesis and skin homeostasis. Glycoconj. J. 19:249–255.
   PubMed Web of Science ®Google Scholar
• Ezura, Y., Chakravarti, S., Oldberg, A., Chervoneva, I., and Birk, D.E. (2000). Differential expression of lumican and fibromodulin regulate collagen fibrillogenesis in developing mouse tendons. J. Cell Biol. 151:779–788.
   PubMed Web of Science ®Google Scholar
• Izu, Y., Ansorge, H.L., Zhang, G., Soslowsky, L.J., Bonaldo, P., Chu, M.L., and Birk, D.E. (2011). Dysfunctional tendon collagen fibrillogenesis in collagen VI null mice. Matrix Biol. 30:53–61.
   PubMed Web of Science ®Google Scholar
• Zhang, G., Young, B.B., Ezura, Y., Favata, M., Soslowsky, L.J., Chakravarti, S., and Birk, D.E. (2005). Development of tendon structure and function: Regulation of collagen fibrillogenesis. J. Musculoskelet. Neuronal Interact. 5:5–21.
   PubMedGoogle Scholar
• Takeda, U., Utani, A., Wu, J., Adachi, E., Koseki, H., Taniguchi, M., Matsumoto, T., Ohashi, T., Sato, M., and Shinkai, H. (2002). Targeted disruption of dermatopontin causes abnormal collagen fibrillogenesis. J. Invest. Dermatol. 119:678–683.
   PubMed Web of Science ®Google Scholar
• Wallin, R., Wajih, N., Greenwood, G.T., and Sane, D.C. (2001). Arterial calcification: A review of mechanisms, animal models, and the prospects for therapy. Med. Res. Rev. 21:274–301.
   PubMed Web of Science ®Google Scholar
• Kalamajski, S., and Oldberg, A. (2010). The role of small leucine-rich proteoglycans in collagen fibrillogenesis. Matrix Biol. 29:248–253.
   PubMed Web of Science ®Google Scholar
• Vogel, K.G., Paulsson, M., and Heinegård, D. (1984). Specific inhibition of type I and type II collagen fibrillogenesis by the small proteoglycan of tendon. Biochem. J. 223:587–597.
   PubMed Web of Science ®Google Scholar
• Minamitani, T., Ariga, H., and Matsumoto, K. (2004). Deficiency of tenascin-X causes a decrease in the level of expression of type VI collagen. Exp. Cell Res. 297:49–60.
   PubMedGoogle Scholar
• Rajamannan, N.M., Subramaniam, M., Rickard, D., Stock, S.R., Donovan, J., Springett, M., Orszulak, T., Fullerton, D.A., Tajik, A.J., Bonow, R.O., and Spelsberg, T. (2003). Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 107:2181–2184.
   PubMed Web of Science ®Google Scholar
• Garg, V., Muth, A.N., Ransom, J.F., Schluterman, M.K., Barnes, R., King, I.N., Grossfeld, P.D., and Srivastava, D. (2005). Mutations in NOTCH1 cause aortic valve disease. Nature 437:270–274.
   PubMed Web of Science ®Google Scholar
• Acharya, A., Hans, C.P., Koenig, S.N., Nichols, H.A., Galindo, C.L., Garner, H.R., Merrill, W.H., Hinton, R.B., and Garg, V. (2011). Inhibitory role of Notch1 in calcific aortic valve disease. PLoS One 6:e27743.
   PubMed Web of Science ®Google Scholar
• Luo, G., Ducy, P., McKee, M.D., Pinero, G.J., Loyer, E., Behringer, R.R., and Karsenty, G. (1997). Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386:78–81.
   PubMed Web of Science ®Google Scholar
• Schafer, C., Heiss, A., Schwarz, A., Westenfeld, R., Ketteler, M., Floege, J., Muller-Esterl, W., Schinke, T., and Jahnen-Dechent, W. (2003). The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J. Clin. Invest. 112:357–366.
   PubMed Web of Science ®Google Scholar
• Moe, S.M., Reslerova, M., Ketteler, M., O’neill, K., Duan, D., Koczman, J., Westenfeld, R., Jahnen-Dechent, W., and Chen, N.X. (2005). Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int. 67:2295–2304.
   PubMed Web of Science ®Google Scholar
• Mochida, Y., Parisuthiman, D., Pornprasertsuk-Damrongsri, S., Atsawasuwan, P., Sricholpech, M., Boskey, A.L., and Yamauchi, M. (2009). Decorin modulates collagen matrix assembly and mineralization. Matrix Biol. 28:44–52.
   PubMed Web of Science ®Google Scholar
• Chalajour, F., Treede, H., Ebrahimnejad, A., Lauke, H., Reichenspurner, H., and Ergun, S. (2004). Angiogenic activation of valvular endothelial cells in aortic valve stenosis. Exp. Cell Res. 298:455–464.
   PubMed Web of Science ®Google Scholar
• Dvorak, H.F., Brown, L.F., Detmar, M., and Dvorak, A.M. (1995). Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146: 1029–1039.
   PubMed Web of Science ®Google Scholar
• Lee, Y.J., Lee, H.J., Choi, S.H., Jin, Y.B., An, H.J., Kang, J.H., Yoon, S.S., and Lee, Y.S. (2012). Soluble HSPB1 regulates VEGF-mediated angiogenesis through their direct interaction. Angiogenesis 15: 229–242.
   PubMed Web of Science ®Google Scholar
• New, S.E., and Aikawa, E. (2011). Cardiovascular calcification: An inflammatory disease. Circ. J. 75:1305–1313.
   PubMed Web of Science ®Google Scholar
• Bathon, J.M., Hwang, J.J., Shin, L.H., Precht, P.A., Towns, M.C., and Horton Jr., W.E. (1994). Type VI collagen-specific messenger RNA is expressed constitutively by cultured human synovial fibroblasts and is suppressed by interleukin-1. Arthritis Rheum. 37:1350–1356.
   PubMed Web of Science ®Google Scholar